M&G plc’s Blueprint Medicines BPMC Stock Holding History

M&G plc’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-97,861	Closed	-$9.1M	–	422
2024 Q3	$9.1M	Buy	+97,861	New	+$9.72M	0.03%	234

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

M&G plc's BPMC Position: Q4 2024 in Review

M&G plc sold out of Blueprint Medicines (BPMC) in Q4 2024, closing a stake of 97,861 shares — an estimated $9.1M sold.

M&G plc first reported a position in BPMC in Q3 2024 and held it in 1 quarter. The position peaked at $9.1M in Q3 2024. 345 funds tracked by Wall St. Rank hold BPMC as of Q4 2024.

M&G plc reported no remaining Blueprint Medicines position as of Q4 2024 after selling out during the quarter.
M&G plc sold 97,861 Blueprint Medicines shares in Q4 2024, an estimated $9.1M.
M&G plc first reported a position in Blueprint Medicines in Q3 2024 and held it in 1 quarter.
M&G plc's Blueprint Medicines position peaked at $9.1M in Q3 2024.
345 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2024.

Based on M&G plc's 13F filing for Q4 2024, filed 11 Feb 2025.